The Claim
In patients at high cardiovascular risk, the addition of ezetimibe to statin therapy has no meaningful effect on all-cause mortality or cardiovascular death over a six-year follow-up period.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people at high risk of heart disease, adding ezetimibe to statin medication does not reduce the chance of dying from any cause or from cardiovascular disease over six years.
See the scientific wording
Adding ezetimibe to statin therapy in patients at high cardiovascular risk has no convincing effect on all-cause mortality or cardiovascular death, with moderate-certainty evidence indicating no meaningful reduction in risk over six years of follow-up.
Lowering LDL cholesterol with statins alone gets it below the level where more reduction makes a difference in survival. Adding ezetimibe lowers LDL even more, but the body does not respond with fewer deaths because the critical danger from cholesterol has already been addressed.
What the research says
1 studyAdding ezetimibe to statins doesn't seem to help people live longer or avoid dying from heart problems, even though it might lower the chance of a heart attack or stroke. The study looked at lots of high-risk patients for six years and found no difference in deaths.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.